ONC — Oncimmune Holdings Income Statement
0.000.00%
Last trade - 00:00
- £20.46m
- £22.56m
- £1.15m
2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 August 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | PRESS | PRESS |
Standards: | IFRS | IFRS | IFRS | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.171 | 0.509 | 3.72 | 3.86 | 1.15 |
Cost of Revenue | |||||
Gross Profit | -0.859 | -0.028 | 2.86 | 1.46 | 0.792 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 8.76 | 9.78 | 8.87 | 12.4 | 5.08 |
Operating Profit | -8.59 | -9.27 | -5.14 | -8.59 | -3.92 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -8.55 | -9.78 | -5.7 | -9.53 | -5.93 |
Provision for Income Taxes | |||||
Net Income After Taxes | -8.01 | -8.46 | -4.63 | -9.51 | -6.15 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -8.01 | -8.46 | -4.63 | -9.51 | 4.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -8.01 | -8.46 | -4.63 | -9.51 | 4.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.13 | -0.14 | -0.072 | -0.137 | -0.085 |